Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
546 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (323)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01478321 | Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas | terminated | Phase 2 | 54 | Northwestern UniversityOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02533700 |
| CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL |
| unknown |
| Phase 2 |
| 106 |
| Shandong Provincial HospitalOTHER_GOV |
| 1 |
| Mar 10, 2020 |
| clinicaltrials |
| NCT02715297 | Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma(GlioCave/NOA17) | unknown | Phase 2 | 162 | Technical University of MunichOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT01349036 | A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma | terminated | Phase 2 | 38 | Daiichi SankyoINDUSTRY | 1 | Mar 3, 2020 | clinicaltrials |
| NCT01967810 | ANG1005 in Patients With Recurrent High-Grade Glioma | completed | Phase 2 | 73 | Angiochem IncINDUSTRY | 1 | Feb 25, 2020 | clinicaltrials |
| NCT01402063 | PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation | completed | Phase 2 | 63 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01498328 | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma(ReACT) | completed | Phase 2 | 127 | Celldex TherapeuticsINDUSTRY | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02414165 | The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma(Toca5) | terminated | Phase 2 / Phase 3 | 403 | Tocagen Inc.INDUSTRY | 4 | Feb 7, 2020 | clinicaltrials |
| NCT00040846 | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies | completed | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT02754362 | A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT04224441 | Repurposing Chlorpromazine in the Treatment of Glioblastoma(RACTAC) | unknown | Phase 2 | 41 | Marco G Paggi, MD, PhDOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT02465528 | Ceritinib Rare Indications Study in ALK+ Tumors | terminated | Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 27, 2019 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT01975701 | A Phase 2 Study of BGJ398 in Patients With Recurrent GBM | completed | Phase 2 | 26 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 4, 2019 | clinicaltrials |
| NCT00984438 | Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme | withdrawn | Phase 1 / Phase 2 | 0 | University of CincinnatiOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT04157478 | Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma | unknown | Phase 2 | 464 | People's Hospital of Guangxi Zhuang Autonomous RegionOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT00105001 | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 210 | Fred Hutchinson Cancer CenterOTHER | 3 | Oct 30, 2019 | clinicaltrials |
| NCT01756352 | FET-PET for Evaluation of Response of Recurrent GBM to Avastin | completed | Phase 2 | 13 | Marcelo F. Di Carli, MD, FACCOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT01989884 | An Efficacy Study Of Ortataxel In Recurrent Glioblastoma(Ortataxel) | completed | Phase 2 | 45 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Oct 23, 2019 | clinicaltrials |
| NCT00049127 | Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor | completed | Phase 1 / Phase 2 | 64 | Alliance for Clinical Trials in OncologyOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT00892177 | Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme | completed | Phase 2 | 144 | Alliance for Clinical Trials in OncologyOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT02729961 | Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | University of WashingtonOTHER | 1 | Oct 10, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01529827 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 94 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01454596 | CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII | completed | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2019 | clinicaltrials |
| NCT02364206 | Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma(GLYRad) | completed | Phase 1 / Phase 2 | 18 | Centre Jean PerrinOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT01514201 | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2019 | clinicaltrials |
| NCT01839916 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 77 | University of ChicagoOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT00423735 | Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 3 | Jul 24, 2019 | clinicaltrials |
| NCT04004975 | Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib | unknown | Phase 1 / Phase 2 | 50 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jul 2, 2019 | clinicaltrials |
| NCT00262730 | Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM | completed | Phase 2 | 97 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT01564914 | A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma(105GM201) | completed | Phase 2 | 22 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Jun 12, 2019 | clinicaltrials |
| NCT02120287 | Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme | completed | Phase 2 | 16 | Ajay NiranjanOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT00576537 | Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors | completed | Phase 2 | 50 | Cedars-Sinai Medical CenterOTHER | 1 | May 3, 2019 | clinicaltrials |
| NCT03916757 | V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer(GBM) | unknown | Phase 2 | 20 | Immunitor LLCINDUSTRY | 1 | Apr 17, 2019 | clinicaltrials |
| NCT00093964 | Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) | completed | Phase 2 | 81 | EMD SeronoINDUSTRY | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00961090 | Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery | completed | Phase 2 | 72 | Matthew R QuigleyOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT01209442 | Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme | completed | Phase 2 | 30 | University of Colorado, DenverOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT00902577 | MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Apr 8, 2019 | clinicaltrials |
| NCT00509821 | Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma | completed | Phase 2 | 60 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 5, 2019 | clinicaltrials |
| NCT02395692 | Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2019 | clinicaltrials |
| NCT00441142 | Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors(Zactima) | completed | Phase 1 / Phase 2 | 119 | Patrick Y. Wen, MDOTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01186406 | Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) | terminated | Phase 2 | 41 | Duke UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01044966 | A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma | terminated | Phase 1 / Phase 2 | 12 | Medical University of South CarolinaOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT01562197 | A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma(AxiGII) | completed | Phase 2 | 56 | Bart NeynsOTHER | 1 | Jan 24, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Mar 12, 2020source: clinicaltrials